Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

Mechanism Of Action ◽

Kinase Inhibitor ◽

Clinical Development ◽

Reversible Covalent

011 Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

Journal of Investigative Dermatology ◽

10.1016/j.jid.2019.07.014 ◽

2019 ◽

Vol 139 (9) ◽

pp. S216

Author(s):

C.L. Langrish ◽

M.R. Francesco ◽

Y. Xing ◽

J.M. Bradshaw ◽

T.D. Owens ◽

...

Keyword(s):

Tyrosine Kinase ◽

Mechanism Of Action ◽

Kinase Inhibitor ◽

Clinical Development ◽

Reversible Covalent

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.7b01712 ◽

2018 ◽

Vol 61 (6) ◽

pp. 2227-2245 ◽

Cited By ~ 67

Author(s):

James J. Crawford ◽

Adam R. Johnson ◽

Dinah L. Misner ◽

Lisa D. Belmont ◽

Georgette Castanedo ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Clinical Development ◽

Early Clinical Development

Separation of Bruton’s tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography

Journal of Chromatography A ◽

10.1016/j.chroma.2018.12.006 ◽

2019 ◽

Vol 1586 ◽

pp. 106-115 ◽

Cited By ~ 5

Author(s):

Shiuhang Henry Yip ◽

Dauh-Rurng Wu ◽

Peng Li ◽

Dawn Sun ◽

Scott H. Watterson ◽

...

Keyword(s):

Tyrosine Kinase ◽

Supercritical Fluid ◽

Supercritical Fluid Chromatography ◽

Kinase Inhibitor ◽

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability

Molecular Pharmaceutics ◽

10.1021/acs.molpharmaceut.8b00702 ◽

2018 ◽

Vol 15 (11) ◽

pp. 5124-5134 ◽

Cited By ~ 4

Author(s):

Stéphanie van Hoppe ◽

Johannes J. M. Rood ◽

Levi Buil ◽

Els Wagenaar ◽

Rolf W. Sparidans ◽

...

Keyword(s):

Cytochrome P450 ◽

Tyrosine Kinase ◽

Oral Bioavailability ◽

Kinase Inhibitor ◽

Cytochrome P450 3A ◽

Brain Penetration ◽

P Glycoprotein

Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853

Organic Process Research & Development ◽

10.1021/acs.oprd.8b00134 ◽

2018 ◽

Vol 22 (8) ◽

pp. 978-990 ◽

Cited By ~ 6

Author(s):

Haiming Zhang ◽

Theresa Cravillion ◽

Ngiap-Kie Lim ◽

Qingping Tian ◽

Danial Beaudry ◽

...

Keyword(s):

Tyrosine Kinase ◽

Manufacturing Process ◽

Kinase Inhibitor ◽

Efficient Manufacturing

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽

10.1182/blood-2017-02-765115 ◽

2017 ◽

Vol 129 (20) ◽

pp. 2808-2810 ◽

Cited By ~ 28

Author(s):

Harriet S. Walter ◽

Sandrine Jayne ◽

Simon A. Rule ◽

Guillaume Cartron ◽

Franck Morschhauser ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Long Term Follow Up

Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib

Future Medicinal Chemistry ◽

10.4155/fmc-2017-0145 ◽

2018 ◽

Vol 10 (3) ◽

pp. 343-356 ◽

Cited By ~ 4

Author(s):

Linyi Liu ◽

Bingyu Shi ◽

Xiangqian Wang ◽

Hua Xiang

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Resistance Mutations ◽

Bruton’s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells

International Immunopharmacology ◽

10.1016/j.intimp.2020.106215 ◽

2020 ◽

Vol 80 ◽

pp. 106215 ◽

Cited By ~ 2

Author(s):

Ahmed Nadeem ◽

Sheikh F. Ahmad ◽

Naif O. Al-Harbi ◽

Ahmad M. El-Sherbeeny ◽

Abullah F Alasmari ◽

...

Keyword(s):

Tyrosine Kinase ◽

Immune Cells ◽

Kinase Inhibitor ◽

Innate Immune ◽

Innate Immune Cells ◽

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

10.1021/bk-2019-1332.ch009 ◽

2019 ◽

pp. 239-266

Author(s):

James J. Crawford ◽

Haiming Zhang

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor

Clinical Pharmacology & Therapeutics ◽

10.1002/cpt.1056 ◽

2018 ◽

Vol 103 (6) ◽

pp. 1020-1028 ◽

Cited By ~ 17

Author(s):

Ann E. Herman ◽

Leslie W. Chinn ◽

Shweta G. Kotwal ◽

Elaine R. Murray ◽

Rui Zhao ◽

...

Keyword(s):

Tyrosine Kinase ◽

Healthy Volunteers ◽

Kinase Inhibitor ◽

Pharmacokinetics And Pharmacodynamics ◽